Xiangdong Wang - Selected Publications#

Dr. WANG has published 400 papers, of which 392 papers were published in English journals and 330 papers in SCI journals (IF>20: 4 papers; IF>10: 40 papers). The published papers have 2113 impact factors, 12701 citations, 58 h-index, and 303 i10-index in total [the number of citations as of September 10, 2021 from Google Scholar (https://scholar.google.com/citations?hl=en&user=HU2ACywAAAAJ)]. His works were cited by a large number of outstanding journals, including Nature Reviews Drug Discovery (IF=85), Lancet (IF=79), Nature Reviews Genetics (IF=53), Nature (IF=50), Nature Genetics (IF=38), Physiological Review (IF=37), Annals of Oncology (IF=33), and Lancet Respiratory Medicine (IF=31).

1. Zhang L, Chen D, Song D, Liu X, Zhang Y, Xu X, Wang X. Clinical and translational values of spatial transcriptomics. Signal Transduct Target Ther. 2022 Apr 1;7(1):111. doi: 10.1038/s41392-022-00960-w.

2. Liu X, Jiang Y, Song D, Zhang L, Xu G, Hou R, Zhang Y, Chen J, Cheng Y, Liu L, Xu X, Chen G, Wu D, Chen T, Chen A, Wang X. Clinical challenges of tissue preparation for spatial transcriptome. Clin Transl Med. 2022 Jan;12(1):e669. doi: 10.1002/ctm2.669.

3. Zhu Z, Zhang L, Lv J, Liu X, Wang X. Trans-omic profiling between clinical phenoms and lipidomes among patients with different subtypes of lung cancer Clin Transl Med. 2020 Aug;10(4):e151. doi:10.1002/ctm2.151.

4. Sun Y, Wu L, Zhong Y, Zhou K, Hou Y, Wang Z, Zhang Z, Xie J, Wang C, Chen D, Huang Y, Wei X, Shi Y, Zhao Z, Li Y, Guo Z, Yu Q, Xu L, Volpe G, Qiu S, Zhou J, Ward C, Sun H, Yin Y, Xu X, Wang X, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell. 2021 Jan 21;184(2):404-421.e16.

5. Dong LQ, Peng LH, Ma LJ, Liu DB, Zhang S, Luo SZ, Rao JH, Zhu HW, Yang SX, Xi SJ, Chen M, Xie FF, Li FQ, Li WH, Ye C, Lin LY, Wang YJ, Wang XY, Gao DM, Zhou H, Yang HM, Wang J, Zhu SD, Wang X, et al. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma. J Hepatol. 2020 May;72(5):896-908. doi: 10.1016/j.jhep.2019.12.014.

6. Zhang D, Song D, Shi L, Sun X, Zheng Y, Zeng Y, Wang X. Mechanisms of interactions between lung-origin telocytes and mesenchymal stem cells to treat experimental acute lung injury. Clin Transl Med. 2020 Dec;10(8):e231. doi:10.1002/ctm2.231.

7. Cao X, Hou J, An Q, Assaraf YG, Wang X. Towards the overcoming of anticancer drug resistance mediated by p53 mutations. Drug Resist Updat. 2020 Mar;49:100671. doi: 10.1016/j.drup.2019.100671.

8. Huang A, Zhao X, Yang XR, Li FQ, Zhou XL, Wu K, Zhang X, Sun QM, Cao Y, Zhu HM, Wang XD, et al. Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma. J Hepatol. 2017 Aug;67(2):293-301. doi: 10.1016/j.jhep.2017.03.005.

9. Liu R, Wang X, Aihara K, Chen L. Early diagnosis of complex diseases by molecular biomarkers, network biomarkers, and dynamical network biomarkers. Med Res Rev. 2014 May;34(3):455-78. doi: 10.1002/med.21293.

10. Wang DC, Wang W, Zhu B, Wang X. Lung Cancer Heterogeneity and New Strategies for Drug Therapy. Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:531-546. doi: 10.1146/annurev-pharmtox-010716-104523.